Corvus Pharmaceuticals, Inc.: shareholders and insiders

CRVSNASDAQHealthcare · Pharmaceutical Preparations

Price

$9.67

November 20, 2026Market cap $812M

What Ploutos Investor adds for Corvus Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 11 fiscal years, from 2015
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 22, 2025 to Nov 13, 2026, from their own Form 4 filings.

6 Form 4s

Bought on the market

$384.2K

3 people

Sold on the market

–

nobody

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

No sales in the period.

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $384.1K by 3 people·no sales

  • 2025: no buys, no sales
  • 2026: bought $384.1K by 3 people, no sales
  • Nov 13, 2026Jeffrey ArcaraChief Business Officer
    Kind
  • Nov 13, 2026Jeffrey ArcaraChief Business Officer
    Kind
  • Nov 12, 2026Jeffrey ArcaraChief Business Officer
    Kind
  • Nov 11, 2026Jeffrey ArcaraChief Business Officer
    Kind
  • Jun 11, 2026David Scott MooreDirector
    Kind
  • May 18, 2026Richard A Md MillerPresident and CEO
    Kind
  • May 18, 2026Richard A Md MillerPresident and CEO
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 15, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by CRVS's officers and directors from 2016 up to November 21, 2025, 10 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

4 Holders over 5%1 On a 13DNov 10, 2026 Latest filing
  • Orbimed Advisorswith 1 more person
    Share of class10.3%
  • Richard A. Millerwith 2 more persons
    Share of class7.80%
  • BlackRock, Inc.
    Share of class7.50%
  • Sirenia Capital Management LPwith 1 more person
    Share of class7.50%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • Orbimed Advisors10.3%From the filing of Jan 27, 2026

    The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the…

    From the filing of Jan 27, 2026
Fell to 5% or less (5)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • State Street4.00%Nov 10, 202613G
  • Point72 Asset Management, L.P.0.00%May 15, 202613G/A
  • The Vanguard Group0.00%Mar 26, 202613G/A
  • Adams Street Partners, LLC13D3.90%Feb 5, 202613D/A
  • Samlyn Capital0.00%Aug 14, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter-42%
  • Citadel Advisors (Griffin)
    In the quarter+0.5%
  • D.E. Shaw
    In the quarter+18%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 21.4% of its shares outstanding were held short, +1.0% since the report before.

Shares held short
17.97M
21.4%
Since the report before17.80M on Sep 30, 2026
+1.0%
14.9
1.20M
More days to cover thanof 4,578 US-listed companies with enough volume
98%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 1.71M
  • Nov 15, 2023: Shares held short 1.79M
  • Nov 30, 2023: Shares held short 1.57M
  • Dec 15, 2023: Shares held short 1.30M
  • Dec 29, 2023: Shares held short 1.33M
  • Jan 12, 2024: Shares held short 1.40M
  • Jan 31, 2024: Shares held short 1.38M
  • Feb 15, 2024: Shares held short 1.27M
  • Feb 29, 2024: Shares held short 1.27M
  • Mar 15, 2024: Shares held short 1.49M
  • Mar 28, 2024: Shares held short 1.40M
  • Apr 15, 2024: Shares held short 1.37M
  • Apr 30, 2024: Shares held short 1.36M
  • May 15, 2024: Shares held short 1.29M
  • May 31, 2024: Shares held short 1.52M
  • Jun 14, 2024: Shares held short 1.50M
  • Jun 28, 2024: Shares held short 1.43M
  • Jul 15, 2024: Shares held short 1.25M
  • Jul 31, 2024: Shares held short 1.15M
  • Aug 15, 2024: Shares held short 1.37M
  • Aug 30, 2024: Shares held short 1.43M
  • Sep 13, 2024: Shares held short 1.64M
  • Sep 30, 2024: Shares held short 2.15M
  • Oct 15, 2024: Shares held short 2.44M
  • Oct 31, 2024: Shares held short 2.93M
  • Nov 15, 2024: Shares held short 3.30M
  • Nov 29, 2024: Shares held short 3.51M
  • Dec 13, 2024: Shares held short 4.31M
  • Dec 31, 2024: Shares held short 5.43M
  • Jan 15, 2025: Shares held short 5.50M
  • Jan 31, 2025: Shares held short 6.11M
  • Feb 14, 2025: Shares held short 5.73M
  • Feb 28, 2025: Shares held short 5.35M
  • Mar 14, 2025: Shares held short 5.39M
  • Mar 31, 2025: Shares held short 4.92M
  • Apr 15, 2025: Shares held short 5.34M
  • Apr 30, 2025: Shares held short 5.77M
  • May 15, 2025: Shares held short 7.23M
  • May 30, 2025: Shares held short 7.08M
  • Jun 13, 2025: Shares held short 7.94M
  • Jun 30, 2025: Shares held short 8.90M
  • Jul 15, 2025: Shares held short 8.98M
  • Jul 31, 2025: Shares held short 8.79M
  • Aug 15, 2025: Shares held short 9.29M
  • Aug 29, 2025: Shares held short 9.59M
  • Sep 15, 2025: Shares held short 9.67M
  • Sep 30, 2025: Shares held short 10.10M
  • Oct 15, 2025: Shares held short 8.83M
  • Oct 31, 2025: Shares held short 9.03M
  • Nov 14, 2025: Shares held short 9.90M
  • Nov 28, 2025: Shares held short 9.81M
  • Dec 15, 2025: Shares held short 9.38M
  • Dec 31, 2025: Shares held short 11.82M
  • Jan 15, 2026: Shares held short 11.49M
  • Jan 30, 2026: Shares held short 14.68M
  • Feb 13, 2026: Shares held short 14.88M
  • Feb 27, 2026: Shares held short 16.01M
  • Mar 13, 2026: Shares held short 16.05M
  • Mar 31, 2026: Shares held short 16.95M
  • Apr 15, 2026: Shares held short 16.93M
  • Apr 30, 2026: Shares held short 18.39M
  • May 15, 2026: Shares held short 18.91M
  • May 29, 2026: Shares held short 17.32M
  • Jun 15, 2026: Shares held short 17.88M
  • Jun 30, 2026: Shares held short 18.82M
  • Jul 15, 2026: Shares held short 18.06M
  • Jul 31, 2026: Shares held short 18.31M
  • Aug 14, 2026: Shares held short 19.13M
  • Aug 31, 2026: Shares held short 19.02M
  • Sep 15, 2026: Shares held short 17.18M
  • Sep 30, 2026: Shares held short 17.80M
  • Oct 15, 2026: Shares held short 17.97M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading53.3% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 53.3% of the shares in the reported trades were short sales, against 59.2% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
53.3%
The 14 beforeOct 14, 2026 – Nov 2, 2026
59.2%
Change
-5.9 pts
Short sales a dayon average, of 350.2K shares
186.8K
More than atof 3,666 US-listed companies, same days
60%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 57.7%
  • Oct 15, 2026: Short sales 61.8%
  • Oct 16, 2026: Short sales 60.8%
  • Oct 19, 2026: Short sales 59.2%
  • Oct 20, 2026: Short sales 54.6%
  • Oct 21, 2026: Short sales 61%
  • Oct 22, 2026: Short sales 66.2%
  • Oct 23, 2026: Short sales 65%
  • Oct 26, 2026: Short sales 56.1%
  • Oct 27, 2026: Short sales 57.2%
  • Oct 28, 2026: Short sales 49.7%
  • Oct 29, 2026: Short sales 59.6%
  • Oct 30, 2026: Short sales 53.9%
  • Nov 2, 2026: Short sales 65.1%
  • Nov 3, 2026: Short sales 42.8%
  • Nov 4, 2026: Short sales 68.3%
  • Nov 5, 2026: Short sales 47.4%
  • Nov 6, 2026: Short sales 57.2%
  • Nov 9, 2026: Short sales 56.3%
  • Nov 10, 2026: Short sales 43%
  • Nov 11, 2026: Short sales 55.1%
  • Nov 12, 2026: Short sales 79.4%
  • Nov 13, 2026: Short sales 59.3%
  • Nov 16, 2026: Short sales 56.6%
  • Nov 17, 2026: Short sales 39.6%
  • Nov 18, 2026: Short sales 38.1%
  • Nov 19, 2026: Short sales 46%
  • Nov 20, 2026: Short sales 45.7%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

16.28M Insiders' shares19.39% Of the company
  • Peter A. ThompsonDirector,TenPercentOwner
    Directly–
  • Orbimed Advisors LlcDirector,TenPercentOwner
    Directly–
  • Richard A Md MillerPresident and CEO
    Directly577.6K
  • William Benton JonesSee Remarks
    Directly153.8K
  • David Scott MooreDirector
    Directly21.7K
  • Jeffrey ArcaraChief Business Officer
    Directly4,500

A lower bound: it counts only the 6 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

13 ETFs holding it0.41% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.41%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.27%
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.22%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.07%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.06%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.03%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.03%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.01%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.01%
  • ONEQFidelity Nasdaq Composite Index ETF
    Weight in the fund0.00%

13 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

174 Managers, Q2 2026$1.1B Value of their positions
  • Q3 2025: Managers 102
  • Q4 2025: Managers 124
  • Q1 2026: Managers 166
  • Q2 2026: Managers 174

Institutional investors by quarter

The fund managers holding CRVS, quarter by quarter, from Q1 2016 to Q2 2025, 38 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 174 managers held 70.71M shares, worth $1.1B. During the quarter 39 opened a position, 33 closed one, 67 added and 39 trimmed.

The largest holders, Q2 2026

  • Orbimed Advisors
    In the quarter
  • BlackRock
    In the quarter+16%
  • State Street
    In the quarter+25%
  • Price T Rowe Associates
    In the quarter+30%
  • Vanguard Capital Management
    In the quarter+1.8%
  • Adams Street Partners
    In the quarter
  • Vivo Capital
    In the quarter
  • Wellington Management Group
    In the quarter+18%
  • Perceptive Advisors
    In the quarter+16%
  • Deep Track Capital
    In the quarter

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Corvus Pharmaceuticals's filings show?

Who buys and sells is one part of Corvus Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about CRVS's shareholders

Didn't find what you were looking for?

Ask us
Have CRVS's insiders bought or sold?

From Jun 15, 2026 to Nov 13, 2026 Corvus Pharmaceuticals's insiders bought $300.7K and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.

Which well-known managers hold CRVS?

4 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $7.0M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.